Research
Hormonal
Leptin regulates energy balance by acting on a dispersed neuronal network in the hypothalamus, specifically activating anorexigenic POMC neurons and inhibiting orexigenic NPY/AgRP neurons in the arcuate nucleus.
Leptin works by turning 'off' hunger neurons (NPY/AgRP) and 'on' fullness neurons (POMC). In obesity, this specific circuitry in the brain's arcuate nucleus becomes resistant to the signal.
StrongSupportsVERY_HIGH confidence
Leptin can modulate the activity of both POMC and AgRP neurons. Leptin reduces the expression of NPY/AgRP mRNA... In contrast, leptin activates POMC neurons... Leptin acts on a diffuse neuronal network, including neurons in the Arcuate Nucleus.
Why this rating
Well-established molecular and electrophysiological evidence in animal models.
Source
Leptin Resistance and Obesity
Pablo J. Enriori et al. · Obesity · 2006
DOI 10.1038/oby.2006.319
narrative_reviewCited 265×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In common obesity, endogenous hyperleptinemia fails to inhibit energy intake or increase energy expenditure, a state termed leptin resistance, which is driven by impaired blood-brain barrier transport and intracellular signaling defects (e.g., SOCS-3) in the arcuate nucleus.Good
- Leptin resistance in humans is debated; some studies suggest low-dose leptin can normalize appetite in weight-reduced obese patients, implying that physiological leptin signaling may still function if the system is resensitized after weight loss.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →